论文部分内容阅读
目的探讨疏肝解郁胶囊联合帕罗西丁治疗帕金森病伴抑郁的疗效及不良反应。方法选取我院在2014年3月~2016年8月期间收治80例帕金森病伴抑郁患者,将其随机分为观察组(n=40)和对照组(n=40),对照组40例患者给予帕罗西丁治疗。观察组40例在对照组的治疗基础上加疏肝解郁胶囊治疗。对比观察两组临床治疗效果及其不良反应表现。结果观察组患者的帕金森病评定量表(UPDRS)Ⅰ、Ⅱ、Ⅲ、Ⅳ分量表分以及HAMD评分均显著低于对照组(P<0.05),观察组治疗总有效率90.0%显著高于对照组70.0%,且观察组患者的不良反应发生率35.0%显著低于单纯西医治疗组75.0%,两组比较具有统计学意义(P<0.05)。结论疏肝解郁胶囊联合帕罗西丁治疗帕金森病抑郁状态具有良好的临床疗效,同时能改善患者帕金森病神经症状,且不良反应少,值得在临床上进一步推广应用。
Objective To investigate the curative effect and adverse reactions of Shugan Jieyu capsule combined with paroxetine in the treatment of Parkinson’s disease with depression. Methods Eighty patients with Parkinson’s disease with depression were selected from March 2014 to August 2016 in our hospital. They were randomly divided into observation group (n = 40) and control group (n = 40), and control group (n = 40) Patients were treated with paroxetine. Observation group of 40 cases in the control group based on the treatment of Shugan Jieyu capsule treatment. The clinical effects and adverse reactions of the two groups were compared. Results In the observation group, the scores of I, II, III and IV in the Parkinson’s Disease Rating Scale (UPDRS) and the HAMD score were significantly lower than those in the control group (P <0.05). The total effective rate in the observation group was significantly higher than that in the control group The incidence of adverse reactions was 70.0% in the control group and 35.0% in the observation group, which was significantly lower than that in the Western medicine group (75.0%). There was significant difference between the two groups (P <0.05). Conclusion Shugan Jieyu capsule combined with paroxetine in the treatment of depression in Parkinson’s disease has good clinical efficacy, and can improve the neurological symptoms of Parkinson’s disease in patients with less adverse reactions, it is worth further clinical application.